Drug glossary Immunotherapy

Toripalimab Tuoyi

A drug being studied in colorectal cancer trials. It appears in 23 clinical trials.

Intravenous PD-1

United States Investigational

European Union Not submitted to the EMA

Spain Not available

What it is

Toripalimab is a humanized monoclonal antibody PD-1 inhibitor used in colorectal cancer treatment, particularly for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors. The drug has shown activity in CRC through combination approaches with other agents including cetuximab, irinotecan, regorafenib, and radiation therapy. Toripalimab targets the PD-1 checkpoint pathway to restore anti-tumor immune responses in colorectal malignancies. Clinical applications include both neoadjuvant settings for localized disease and treatment of metastatic colorectal cancer.

How it works

Toripalimab binds to the programmed death-1 (PD-1) receptor on T lymphocytes, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signals that tumors use to evade immune surveillance, thereby reactivating cytotoxic T-cell responses against cancer cells.

Molecular targets

PD-1

Common side effects

FatigueSkin rashPruritusDiarrheaDecreased appetiteNauseaHypothyroidismElevated liver enzymes

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.

Trials with this drug

15 recruiting

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases NCT07277322 Recruiting Phase 1 United States Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study NCT07896681 Recruiting Phase 2 China A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemora… NCT07669220 Recruiting Phase 2 China Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC NCT07281716 Recruiting Phase 1 United States Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer NCT07140679 Recruiting Phase 2 United States Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial NCT07106034 Recruiting Phase 2 China

See all 23 trials

Guides that may help

Written for patients and families, in plain language.

MSI-H / dMMR: what it means and why it changes treatmentMSI-H (high microsatellite instability) and dMMR (deficient mismatch repair) describe the same thing: a tumour that accumulates…Eating during chemotherapy: what the evidence supports and what it does notThere is no "anti-cancer diet" that improves the outcome of chemotherapy. What is proven is that losing weight and muscle during…Cancer-related fatigue: what actually helpsCancer-related fatigue is the most common symptom during and after treatment, and it is not fixed by sleeping more. Before…

See all guides →